Antibodies eye mosquito-transmitted Ross River fever

mosquito net
Credit: CC0 Public Domain

Ross River fever is a mosquito-transmitted disease endemic to Australia and surrounding Pacific Islands. There is no specific treatment or vaccine for Ross River virus (RRV) infection, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

James Crowe Jr., MD, and colleagues isolated a panel of human monoclonal antibodies from the blood of two RRV disease survivors. The monoclonal antibodies potently neutralized RRV infectivity in cell culture and blocked infection through multiple mechanisms. In an immunocompromised mouse model, they significantly reduced viral burden, clinical disease and death.

The findings, reported May 4 in PLOS Pathogens, suggest that therapeutic administration of in early RRV disease may be beneficial in reducing viral load and disease severity.

Antibody treatment also might decrease the likelihood of human-mosquito-human transmission, the researchers added. There is evidence that mosquitoes can pick up the virus after biting infected people, and then transmit it to the next person they bite.

Explore further

Researchers uncover mechanisms of protective antibody response during Marburg infection

More information: Laura A. Powell et al. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease, PLOS Pathogens (2020). DOI: 10.1371/journal.ppat.1008517
Journal information: PLoS Pathogens

Citation: Antibodies eye mosquito-transmitted Ross River fever (2020, May 18) retrieved 15 July 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments